COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

Trial Profile

COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Tisagenlecleucel-T (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COBALT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 01 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top